Abstract
The superantigens cause a massive polyclonal activation of T-cells, producing an immense liberation of proinflamatory cytokines, which induces the clinical data of toxic shock syndrome. In international studies the administration of polyclonal intravenous gammaglobulin has been observed to diminish the mortality 50 to 20%. But at the present it has not been reported in Mexico the clinical effectiveness of this therapeutic modality in toxic shock syndrome. We report three cases of toxic shock syndrome treated with gammaglobulin intravenous, and we describe their favorable clinical evolution.
MeSH terms
-
Bacterial Toxins / chemistry
-
Bacterial Toxins / immunology
-
Bacterial Toxins / pharmacology
-
Cellulitis / complications
-
Chickenpox / complications
-
Child
-
Child, Preschool
-
Cytokines / metabolism
-
Drug Evaluation
-
Enterotoxins / chemistry
-
Enterotoxins / immunology
-
Enterotoxins / pharmacology
-
Female
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use*
-
Lymphocyte Activation
-
Remission Induction
-
Shock, Septic / etiology
-
Shock, Septic / immunology
-
Shock, Septic / mortality
-
Shock, Septic / therapy*
-
Skin / injuries
-
Streptococcal Infections / complications*
-
Streptococcal Infections / etiology
-
Streptococcal Infections / therapy
-
Streptococcus pyogenes
-
Superantigens / chemistry
-
Superantigens / immunology*
-
Superantigens / pharmacology
-
T-Lymphocytes / drug effects
-
T-Lymphocytes / immunology
-
Treatment Outcome
-
Wound Infection / complications*
-
Wound Infection / etiology
-
Wound Infection / therapy
Substances
-
Bacterial Toxins
-
Cytokines
-
Enterotoxins
-
Immunoglobulins, Intravenous
-
Superantigens
-
enterotoxin F, Staphylococcal